StockData

NewAmsterdam Pharma vs vTv Therapeutics

NAMS and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NAMS and VTVT compare

vTv Therapeutics grew revenue faster over the last twelve months (216600% versus −88.9% for NewAmsterdam Pharma).

vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −12.9% compared with −3644% at NewAmsterdam Pharma.

vTv Therapeutics scores higher on the StockData Score (11 against 6 for NewAmsterdam Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNAMSVTVT
Size and price
Market cap–$68.4M
Share price$19.39$17.29
Change, 1 year−49.4%−43.9%
Change, 5 years98.1%−67.7%
Beta (5Y)1.570.08
Employees10026
StockData Score
Total score611 (better)
Valuation score03 (better)
Growth score01 (better)
Performance score12 (better)
Health score55
Dividend score00
Valuation
P/S–1.9×
P/B–0.9×
Fair value–$44.97
Margin of safety–61.6%
Growth
Revenue growth (TTM)−88.9%216600% (better)
Profitability
Operating margin−3432%−25.1% (better)
Net margin−3644%−12.9% (better)
FCF margin−2018%–
Return on equity−36.8%−11.7% (better)
Return on invested capital−1046%–
Financial health
Debt / equity0.000.00
Current ratio9.0312.48 (better)
Altman Z-score–0.71
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–40.6%
Held by insiders22.0%26.3%
Insider net buying, 12 months−$63.0M–
Short interest, % of float–5.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.